

Supplementary Table

Table S1. The risk factors associated with the early rebleeding in EGVB patients in training cohort

Variables	Early rebleeding		Univariate		Multivariate	
	Yes (n=22)	No (n=53)	OR (95% CI)	p value	OR (95% CI)	p value
Age	58 ± 2.8	55.5 ± 1.7	1 (0.4-2.6)	0.446		
WBC (10 ⁹ /L)	7.9 ± 1.1	7.5 ± 0.7	0.9 (0.4-1.9)	0.767		
Hb (g/L)	65.1 ± 4.2	59.8 ± 2.3	1.1 (0.4-2.7)	0.230		
PLT (10 ⁹ /L)	89 ± 14.6	80.7 ± 6.3	0.7 (0.2-1.7)	0.547		
ALT (U/L)	27 (17.5-43.3)	22 (11-46.5)	1.8 (0.7-5)	0.361		
AST (U/L)	37 (26.3, 133)	38 (20, 93)	0.7 (0.3-1.9)	0.442		
TBIL (μmol/L)	48.2 (17.7-135)	30.7 (18.4-69)	1.3 (0.5-3.5)	0.346		
ALB (g/L)	27.7 ± 1.3	26.9 ± 0.8	0.9 (0.3-2.3)	0.591		
CHE (μmol/L)	2284 ± 209	2243 ± 151	1.1(0.6-1.8)	0.886		
PT (s)	17.7 (13.9-27.3)	19 (15.1-24.3)	1 (0.6-1.7)	0.944		
PTA (%)	50.9 ± 4.8	46.4 ± 2.2	1.3 (0.5-3.4)	0.391		
INR	1.71 (1.2-2.5)	1.7 (1.4-2.1)	1.2 (0.7-1.9)	0.745		
CTP scores	11.5 ± 0.6	10.1 ± 0.3	3.3(1.2-9.4)	0.023	1.5 (1.2 - 1.9)	0.003
MELD scores	18.1 ± 2.4	15.4 ± 1.2	1.1(0.4-3)	0.257		
Sex, male	18 (81.8)	37 (69.8)	2 (0.6-6.7)	0.284		
Shock	14 (63.6)	25 (47.2)	0.5 (0.2-1.4)	0.194		
First bleeding	11 (50)	20 (37.7)	0.6 (0.2-1.7)	0.326		
Portal vein emboli	10 (45.5)	22 (41.5)	0.9 (0.3-2.3)	0.753		
Liver cancer	8 (36.4)	11 (20.8)	0.5 (0.2-1.4)	0.157		
Hepatic failure	6 (27.3)	17 (32.1)	1.3 (0.4-3.8)	0.681		
Bleeding site, EV	13 (59.1)	43 (81.1)	3 (1.1 - 8.9)	0.046	5.9 (1.6, 22.1)	0.009
Blakemore tube	10 (45.5)	21 (39.6)	0.8 (0.3-2.2)	0.641		
Treatment			1.6 (0.6-4.4)	0.347		
TAI/EIS/EVL	9 (41.7)	28 (52.8)				
TAI+EIS/EVL	13 (58.3)	25 (47.2)				
HE				0.026		0.265
No	6 (27.3)	31 (58.5)	Reference			
Latent	8 (36.35)	15 (28.3)	2.8 (0.8-9.4)	0.105	2.1 (0.6-8)	0.283
Overt	8 (36.35)	7 (13.2)	3.1 (1.4-7)		3.7 (0.7-19.8)	0.133
Ascites				0.112		
No	0 (0)	6 (11.3)	Reference			
Mild	8 (36.4)	25 (47.2)	4.3 (0.2-86.3)	0.335		
Moderate-severe	14 (63.6)	22 (41.5)	8.4 (0.4-160.3)	0.158		